» Articles » PMID: 24204161

Transient Elastography-based Risk Estimation of Hepatitis B Virus-related Occurrence of Hepatocellular Carcinoma: Development and Validation of a Predictive Model

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2013 Nov 9
PMID 24204161
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of this study was to develop and validate a novel transient elastography-based predictive model for occurrence of hepatocellular carcinoma (HCC).

Methods: A total of 1,250 patients with chronic hepatitis B and baseline liver stiffness values were recruited between May 2005 and December 2007. The predictive model for HCC occurrence was constructed based on a Cox proportional hazards model. We estimated baseline disease-free probabilities at 3 years. Discrimination and calibration were used to validate the model.

Results: HCC occurred in 56 patients during a median follow-up of 30.7 months. Multivariate analysis revealed that age, male gender, and liver stiffness values were independent predictors of HCC (all P<0.05), whereas hepatitis B virus DNA ≥20,000 IU/L showed borderline statistical significance (P=0.0659). We developed a predictive model for HCC using these four variables, which showed good discrimination capability, with an area under the receiver operating characteristic curve (AUROC) of 0.806 (95% confidence interval 0.738-0.874). We used the bootstrap method to assess discrimination. The AUROC remained largely unchanged between iterations, with an average value of 0.802 (95% confidence interval 0.791-0.812). The predicted risk of occurrence of HCC calibrated well with the observed risk, with a correlation coefficient of 0.905 (P<0.001).

Conclusion: This novel model accurately estimated the risk of HCC occurrence in patients with chronic hepatitis B.

Citing Articles

Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults.

Cong X, Song S, Li Y, Song K, MacLeod C, Cheng Y BMC Med. 2024; 22(1):601.

PMID: 39736748 PMC: 11686935. DOI: 10.1186/s12916-024-03754-9.


KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.

Kim M, Han J, An J, Kim B, Jin Y, Kim S Clin Mol Hepatol. 2024; 30(Suppl):S5-S105.

PMID: 39159947 PMC: 11493350. DOI: 10.3350/cmh.2024.0506.


Hepatocellular Carcinoma Risk Scores from Modeling to Real Clinical Practice in Areas Highly Endemic for Hepatitis B Infection.

Hao X, Fan R, Zeng H, Hou J J Clin Transl Hepatol. 2024; 11(7):1508-1519.

PMID: 38161501 PMC: 10752803. DOI: 10.14218/JCTH.2023.00087.


The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.

Yu J, Cho S, Jin Y, Lee J Clin Mol Hepatol. 2021; 28(3):351-361.

PMID: 34823308 PMC: 9293610. DOI: 10.3350/cmh.2021.0281.


Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update.

Lok J, Agarwal K Viruses. 2021; 13(7).

PMID: 34372539 PMC: 8309969. DOI: 10.3390/v13071333.


References
1.
Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

2.
Hann H, Fu X, Myers R, Hann R, Wan S, Kim S . Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort. Eur J Cancer. 2012; 48(15):2319-27. PMC: 3382017. DOI: 10.1016/j.ejca.2012.02.065. View

3.
Calle E, Kaaks R . Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4(8):579-91. DOI: 10.1038/nrc1408. View

4.
Park B, Park Y, Ahn S, Lee K, Chon C, Moon Y . Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol. 2007; 22(3):383-8. DOI: 10.1111/j.1440-1746.2007.04857.x. View

5.
. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2008; 50(2):227-42. DOI: 10.1016/j.jhep.2008.10.001. View